Peli BioThermal opens new service centre in India
It is estimated the state of Gujarat, where Ahmedabad is located, accounts for approximately 30 per cent of the country's pharmaceutical production and exports.
UK-based Peli BioThermal, a temperature-controlled packaging solutions provider, announces the opening of its latest service centre, located in Ahmedabad, India, a major manufacturing hub for pharma companies in the Western part of India.
The new site is a full-service network station offering conditioning and refurbishment services for Peli BioThermal's Crēdo Cargo and Crēdo Xtreme bulk shippers to meet the region's rising requirement for the company's Crēdo on Demand rental program.
"This is the latest development of our rapidly expanding Crēdo on Demand rental program. Ahmedabad is a key site where more than eight of India's largest pharma companies have multiple plants operating, which are all major exporters to markets in Europe and the U.S," said Dominic Hyde, Vice President – Global Services, Peli BioThermal.
"Our market-leading, high-performing products will be readily available for our customers in the region," Hyde expands, "which is an area of significant growth for multiple Clinical Research Organisations conducting clinical trials, another area of growth in India. Peli BioThermal's new India service centre is the latest location in our growing global drop points, service centres and network stations, supporting rental programs to more than 100 locations, as we continue to extensively expand our infrastructure worldwide to better meet the complex needs of our international customers."
An increasing number of leading pharmaceutical companies are located in Ahmedabad including Astra Zeneca, Swiss Pharma and Torrent Pharma. Served by an international airport, Ahmedabad is an important economic hub where numerous pharma companies have R&D facilities based to introduce new products to the market.
It is estimated the state of Gujarat, where Ahmedabad is located, accounts for approximately 30 per cent of the country's pharmaceutical production and exports. Within the global pharma market India provides more than 50 per cent of the worldwide requirement for various vaccines and 40 per cent of the demand for generic products in the United States.
Peli BioThermal's new India facility is the latest in the company's ongoing plans to add new service centres to support its expanded offerings, growing its already robust and unmatched global network.